RU 28965

Known as: RU-28965, RU28965 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1984-1988
051019841988

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1987
1987
The penetration of roxithromycin (RU 28965), an ether oxime derivative of erythromycin, into the cells and fluid lining the… (More)
Is this relevant?
1987
1987
The in vitro susceptibility of Mycobacterium avium to RU-28965 alone and in combination with rifampin, isoniazid, and… (More)
Is this relevant?
1987
1987
The in vitro susceptibility of Mycobacterium tuberculosis to a new macrolide antibiotic RU-28965, alone and in combination with… (More)
Is this relevant?
1987
1987
The minimal inhibitory concentrations of macrolide antibiotics against staphylococci, streptococci and Haemophilus influenzae… (More)
Is this relevant?
1986
1986
Roxithromycin (RU 28965), an ether oxime derivative of erythromycin, protected mice against a lethal infection with the virulent… (More)
Is this relevant?
1986
1986
The activity of a novel macrolide, RU 28965, was compared to that of erythromycin against Gram-positive organisms isolated mainly… (More)
Is this relevant?
1986
1986
The in vitro effects of RU 28965 (roxithromycin), a new semisynthetic macrolide, on human neutrophil activity were compared with… (More)
Is this relevant?
1985
1985
The in vitro activity of drugs currently used in the treatment of diarrhea against 595 enteropathogens from worldwide sources was… (More)
Is this relevant?
1985
1985
The plasma concentration of RU 28965, a new semisynthetic macrolide, was monitored for 24 h after single 400 mg oral doses in 8… (More)
Is this relevant?
1984
1984
RU 28965, a novel macrolide antibiotic, inhibited most gram-positive species at concentrations similar to that of erythromycin… (More)
Is this relevant?